Vol 7, No 5 (2011)
Review paper
Published online: 2011-12-09
Molecularly-targeted therapy of gastric cancer
Onkol. Prak. Klin 2011;7(5):258-263.
Abstract
Gastric cancer is a heterogeneous malignancy with expression of many molecular factors. Trastuzumab
is the first biologic drug (targeted therapy) that has shown benefits in terms of increased median
overall survival. Trastuzumab in combination with chemotherapy is indicated in metastatic gastric or
gastrooesophageal junction cancer in patients with no prior exposure to systemic anticancer therapy for
disseminated disease and with HER2 protein overexpression (score of IHC 3+) regardless of HER2 gene
copy number and with expression of 2+ combined with HER2 gene amplification, although clinical benefits
in this group are much less evident.
Onkol. Prak. Klin. 2011; 7, 5: 258–263
Onkol. Prak. Klin. 2011; 7, 5: 258–263
Keywords: gastric cancertargeted therapytrastuzumab